Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
11 Mar, 26
New guidelines on pulmonary embolism (PE) offer evidence based recommendations for evaluating, managing, and following up adults with acute PE. Endorsed by eight societies, it stresses multidisciplinary care across emergency, inpatient, & outpatient settings.
26 Feb, 26
ADA 2026 outlines the standards for obesity pharmacotherapy. It recommends combining person-centered medication with lifestyle changes for adults with obesity. It details weight-loss targets and drug benefits for comorbidities
6 Mar, 26
Cardiovasc Diabetol.
- In 6,847 metabolic dysfunction-associated steatotic liver disease (MASLD) patients (median follow-up 8.8 yrs), 19.6% died (6.5% CV, 1.3% diabetes)
- Higher estimated glucose disposal rate (eGDR) was linked to reduced all-cause (HR=0.94, P < 0.001), CV (HR=0.90, P < 0.001), & diabetes mortality (HR=0.70, P < 0.001)
- ROC AUCs: 0.606, 0.631, 0.729 respectively, eGDR shows prognostic relevance in MASLD.
5 Mar, 26Mov Disord.
- As per a long-term follow-up study of 15.7 years, higher long term exposure to air pollutants like fine particulate matter (PM2.5), nitrogen dioxide, and black carbon increased Parkinson’s disease risk (hazard ratios per interquartile range were 1.05, 1.03, 1.04, resp.)
- Warm season ozone showed a slight inverse association (HR 0.98)
- Findings supported that air pollution was a risk factor for Parkinson’s disease.
4 Mar, 26BMJ Open Res Clin.
- As per the analysis of 2016–2021 NIS data of adults with T1DM hospitalized for DKA, sex–age interactions influenced outcomes
- Women had lower AKI odds (aOR 0.56, 0.71, 0.79 across age groups) but higher sepsis odds (aOR 1.66, 1.31, 1.17; all p<0.05)
- Mortality benefit for women was limited to ages 18–44 (aOR 0.72)
- COVID-19 years saw mortality rise across all groups, most in young men (from 0.48% to 0.89%)
2 Mar, 26Eur Urol
- This randomized study showed that biparametric MRI‑first screening, regardless of PSA levels increased biopsy (10.8% vs 5.2%) and csPCa detection (4.6% vs 1.8%) as compared to those who received bpMRI only if PSA >3 ng/ml
- Benefit–harm metrics favored MRI first, with higher grade selectivity, biopsy efficiency, and biopsy avoidance
- The strategy was cost effective with no serious adverse events.
The speaker highlighted Secukinumab’s expanding role in psoriasis care, emphasizing its strong data on clear-skin outcomes, sustained efficacy, favorable safety, and robust benefits in managing psoriatic comorbidities including PsA.
Featured
6 Mar, 26
4 Mar, 26
25 Feb, 26
